The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/48909

Please be advised that this information was generated on 2017-08-26 and may be subject to change.
**ABSTRACT**

Background: Mutations of the **NOD2** gene increase the susceptibility of humans to Crohn’s disease. **NOD2** is a cytoplasmic receptor for the bacterial product peptidoglycan. There is considerable controversy in the literature whether the most common mutation in Crohn’s disease, the 3020insC **NOD2**, leads to a loss of function, i.e. decreased cytokine production, or to the reverse, i.e. a gain of function. In previous papers we proposed the former, since we could show decreased cytokine production with a net proinflammatory status after exposure to muramyl dipeptide (MDP).

Methods: Because of recent data in the literature showing increased interleukin-1β (IL-1β) production in mice with the corresponding **NOD2** mutation, we investigated the production of this cytokine by cells of patients with Crohn’s disease, either homozygous or heterozygous for the 3020insC mutation, and compared it with that of patients with Crohn’s disease bearing the wild-type allele.

Results: A strongly decreased production of IL-1β by peripheral mononuclear cells was found upon exposure to either peptidoglycan or peptidoglycan-derived MDP in homozygous patients bearing the 3020insC **NOD2** mutation, and compared it with that of patients with Crohn’s disease bearing the wild-type allele.

Conclusion: This sustains the hypothesis that the 3020insC mutation in the human **NOD2** gene leads to a loss-of-function phenotype.

**KEYWORDS**

Crohn’s disease, cytokine, IL-1, **NOD2**
leads to activated inflammation (‘gain of function’). So far, we have been more in favour of the loss-of-function hypothesis as we obtained experimental evidence for a defective response to peptidoglycan and MDP in cells with this mutation. Recently, however, Maeda et al. proposed a gain-of-function effect of NOD2 mutations based on the finding of greater IL-1β release in MDP-stimulated cells of mice bearing an NOD2 mutation that corresponds to the human 3020insC mutation. Prompted by the intriguing findings of Maeda et al. on the increased IL-1β processing, we measured mature IL-1β released by the mononuclear cells of patients with the 3020insC mutation, after stimulation with either peptidoglycan, or a combination of MDP with the lipoprotein MALP-2, a Toll-like receptor-2 (TLR2) agonist. The latter stimulation was investigated, because we recently demonstrated synergy between the cell surface pattern recognition receptor TLR2 and the cytoplasmic NOD2.11

MATERIALS AND METHODS

Genotyping of NOD2 variants
Blood was collected from 74 patients with Crohn’s disease and ten healthy volunteers. Polymerase chain reaction (PCR) amplification of NOD2 gene fragments containing the polymorphic site 3020insC was performed in 50 µl reaction volumes containing 100 to 200 ng genomic DNA, as previously described.10 The 3020insC polymorphism was analysed by Genescan analysis on an ABI Prism 3100 Genetic Analyser according to the manufacturer’s protocol (Applied Biosystems, Nieuwerkerk a/d IJssel, the Netherlands) and the number was adjusted to 5 x 10^6 cells/ml.

Next, 5 x 10^5 MNC in a 100 µl volume were added to round-bottom 96-well plates (Greiner, Alphen a/d Rijn, the Netherlands) and incubated with either 100 µl of culture medium (negative control), MDP (10 µg/ml, Sigma Chemical Co, St. Louis), purified staphylococcal peptidoglycan (1 µg/ml), or MALP2 lipopeptides (1 µg/ml, EMC Microcollections, Tübingen, Germany).

Cytokine measurements
Human IL-1β concentrations were determined by specific radioimmunoassays as previously described.12

Statistical analysis
The experiments were performed in triplicate with blood obtained from patients and volunteers. The differences between groups were analysed by the Mann-Whitney U test, and where appropriate by the Kruskal-Wallis ANOVA test. The level of significance between groups was set at p<0.05. The data are given as means ± SEM.

RESULTS

The release of IL-1β after stimulation with peptidoglycan or MDP did not differ between healthy volunteers and patients with Crohn’s disease who were either heterozygous for the mutation or had no mutation (figure 1). In contrast, patients homozygous for the mutation exhibited a strongly decreased IL-1β synthesis in response to both peptidoglycan or MDP (figure 1).

To investigate whether the mutated NOD2 leads to modified synergism between NOD2- and TLR2-mediated signalling, cells from the patients with the 3020insC mutation were stimulated with a combination of MDP and the lipoprotein MALP-2, a specific TLR2 agonist (figure 2). MDP and MALP-2 appeared to have synergistic effects on IL-1β release of normal cells; these effects were absent in patients with the 3020insC mutation, arguing that the 3020insC mutation induces a loss-of-function phenotype.

DISCUSSION

In this paper, we demonstrate that peripheral blood mononuclear cells of patients suffering from Crohn’s disease with the 3020insC NOD2 mutation are defective in terms of IL-1β production when stimulated with the NOD2 ligands MDP and peptidoglycan. These results argue for a lack-of-function character of the mutation and are fundamentally different from those obtained in mice with the equivalent mutation.13
The low IL-1β production in humans with the mutation is in agreement with previous studies from both our laboratory and others demonstrating decreased production of other proinflammatory cytokines in these patients. Likewise, Li et al. have shown reduced IL-1β release in mononuclear cells from two patients with homozygous 3020insC mutation when stimulated with a combination of MDP and TNF. These human studies are, however, at odds with the increased IL-1β production in mice genetically engineered to have the same NOD2 mutation as the human 3020insC mutation, which suggested a gain-of-function phenotype of this mutation. Proponents of the gain-of-function hypothesis have argued that the cells from patients with the 3020insC mutation suffer from active inflammatory disease and therefore may have downregulated cytokine production, as is commonly found in other inflammatory conditions. This is, however, very unlikely for a variety of reasons. First of all, patients with Crohn’s disease bearing the 3020insC mutation had lower cytokine production only after stimulation with the NOD2 ligands peptidoglycan and MDP, but not after the TLR2 agonist MALP-2 in this study (figure 2), or other TLR ligands as shown in previous studies. If an inhibition of cytokine production due to inflammation had been present, a general downregulation of both NOD2- and TLR-induced cytokines should have been found. Secondly, an inflammation-driven downregulated proinflammatory cytokine production tends to be associated with an upregulated anti-inflammatory cytokine response. This is not the case here: we have previously demonstrated that the anti-inflammatory response as exemplified by IL-10 production is strongly inhibited. An explanation for the increased inflammation in mice bearing the variant NOD2 could have been the lack of inhibitory signals on TLR2-induced cytokine release, leading to increased cytokine production, as recently proposed by Watanabe et al. Unfortunately, Maeda et al. inappropriately tested this hypothesis by using PGN as a putative TLR2 ligand, and stimulating cells with a combination of MDP and PGN. PGN is in fact the bacterial product containing the MDP motif, and thus an NOD2 ligand. The TLR2-dependent activity of PGN has been convincingly shown to be due to contamination with lipoteichoic acid. To settle the argument whether the lack of functional NOD2 would lead to enhanced TLR2-mediated signals, we stimulated cells from the patients bearing the 3020insC mutation with a combination of MDP and the lipoprotein MALP-2, a specific TLR2 agonist (figure 2). We have shown here that MDP and MALP-2 have synergistic effects on IL-1β release, and these effects were absent in patients with the 3020insC mutation, arguing that an NOD2-mediated suppression of TLR2 signals does not play an important role in patients with Crohn’s disease.
What could the explanation be for the apparent discrepancies between 3020insC-positive Crohn’s patients and NOD2 variant mice? Most likely, there are crucial differences between the murine and human NOD2 systems. This may also explain why humans with NOD2 mutations develop Crohn’s disease, whereas mice deficient for NOD2 do not show any signs of inflammation.20 The mechanisms through which the mutations in the NOD2 gene result in chronic intestinal inflammation in humans are likely mediated by two pathways: firstly through decreased defence against intestinal pathogens that trigger the initial inflammatory reaction,21 and secondly through loss-of-control of the intestinal inflammation due to the defective release of anti-inflammatory cytokines such as IL-10 and TGFβ.10

ACKNOWLEDGEMENTS

M.G. Netea was supported by a VIDI grant from the Netherlands Organisation for Scientific Research (NWO-ZonMW).

REFERENCES